Match!
Bernd Pötzsch
University of Bonn
Molecular biologyChemistryImmunologyThrombinMedicine
121Publications
25H-index
3,306Citations
What is this?
Publications 114
Newest
#1Tobias Becher (Heidelberg University)H-Index: 9
#2Jens Müller (University of Bonn)H-Index: 22
Last. Dirk Loßnitzer (Heidelberg University)H-Index: 5
view all 8 authors...
Septic shock is characterized by a dysregulated response to infection, hypotension and activation of the coagulation system. Markers of coagulation activation are commonly used to diagnose and monitor ensuing coagulopathies. In this study, we sought to determine levels of circulating thrombin in patients with septic shock. To characterize levels of circulating, active thrombin in patients with septic shock. 48 patients with septic shock were included in this prospective, observational study. Blo...
Source
#1Sara Reda (University Hospital Bonn)H-Index: 1
#2Franziska Isabelle Winterhagen (University Hospital Bonn)H-Index: 1
Last. Heiko Rühl (University Hospital Bonn)H-Index: 6
view all 7 authors...
Source
#1Heiko Rühl (University Hospital Bonn)H-Index: 6
#2Sara Reda (University Hospital Bonn)H-Index: 1
Last. Bernd Pötzsch (University Hospital Bonn)H-Index: 25
view all 7 authors...
Source
#1Christina Berens (University Hospital Bonn)H-Index: 2
#2Jens Müller (University Hospital Bonn)H-Index: 22
Last. Bernd Pötzsch (University Hospital Bonn)H-Index: 25
view all 5 authors...
Source
#1Jens MüllerH-Index: 22
Last. Johannes OldenburgH-Index: 60
view all 10 authors...
Source
#1Heiko Rühl (University Hospital Bonn)H-Index: 6
#2Christina Berens (University Hospital Bonn)H-Index: 2
Last. Bernd Pötzsch (University Hospital Bonn)H-Index: 25
view all 7 authors...
Rationale: Carriers of the most common prothrombotic mutations factor V Leiden (FVL) and prothrombin (FII) 20210G>A show a highly variable clinical phenotype. Using standardized in vivo coagulation...
Source
#1Jens Müller (University of Bonn)H-Index: 22
#2Isabell Pekrul (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Michael Spannagl (LMU: Ludwig Maximilian University of Munich)H-Index: 40
view all 6 authors...
Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is the development of neutralizing alloantibodies, known as FVIII inhibitors. HA patients who develop FVIII inhibitors have limited treatment options available to them and experience greater disease- and treatment-related burdens than HA patients without FVIII inhibitors. Emicizumab, a recently approved bispecific mon...
Source
#1Charlotte A. Bäuml (University of Bonn)H-Index: 3
#2Thomas Schmitz (University of Bonn)H-Index: 3
Last. Diana Imhof (University of Bonn)H-Index: 18
view all 12 authors...
Tridegin is a potent and specific 66mer peptide inhibitor of coagulation factor XIIIa with six cysteines involved in three disulfide bonds. Three of the 15 possible 3-disulfide-bonded isomers have been identified, which share a bridge between cysteines 19 and 25. We synthesized the three possible 2-disulfide-bonded analogues using a targeted protecting group strategy to investigate the impact of the C19–C25 bond on tridegin’s folding, stability, and function. The FXIIIa inhibitory activity of th...
Source
#1Christina Berens (University Hospital Bonn)H-Index: 2
#2Heiko Rühl (University Hospital Bonn)H-Index: 6
Last. Bernd Pötzsch (University Hospital Bonn)H-Index: 25
view all 5 authors...
Source
Last. Bernd PötzschH-Index: 25
view all 4 authors...
Source
12345678910